Oyster Point is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapies for diseases presenting great unmet needs whose pathophysiology includes parasympathetic pathways. Our lead candidates are in Phase 2 clinical trials for the treatment of signs and symptoms of dry eye disease.
Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories.
PhD, MMS, CEO
Dr. Nau has built his career on developing novel, innovative therapies for diseases of the eye, with over 15 years of experience working with biotechnology, pharmaceutical, and medical device companies. Most recently, he was VP, Clinical and Medical Affairs, at Ophthotech. Prior to that he was a Medical Science Director at Genentech working on the development of Lucentis®, a transformative drug for retinal diseases. Dr. Nau has raised more than $150 million in equity for start-ups such as Genaera Corporation, Acuity Pharmaceuticals, and NeoVista, Inc. He has numerous patents and peer-reviewed publications
Mark has been a CFO in the life science sector for over 30 years, working with senior executives and their boards. His ophthalmology experience includes the successful exits of OptiMedica and Oculeve. Mark spent over 20 years with Guidant Corporation, where he was part of the senior management team and in its $1 billion IPO thru its exit in 2006 for $27 billion (by Boston Scientific and Abbott Labs). He has helped raise over $1.6 billion in equity and over $500 million in debt for public and private companies. Mark is currently a partner at partner at FLG Partners, LLC. He holds a BS in business administration (accounting) from San Francisco State University.
Loni Da Silva
VP, Regulatory Affairs
Loni has over 30 years of leadership experience in global regulatory affairs and strategic drug development, with more than 20 years in the ophthalmic space. She began her career at Hoffman La-Roche, and most recently served as SVP, Global Regulatory Affairs for Ophthotech, where she worked on wet and dry AMD. Loni has led global regulatory affairs for 3 start-ups and IPOs including Eyetech, Pharmasset, and Ophthotech. In addition to ophthalmology, her experience also includes oncology, antivirals, anti-infectives, hematology, pain management, and cardiology. Loni received her B.S. in microbiology from Penn State University and a M.S. in regulatory affairs from Long Island University.
Dawn Pruitt Koffler
Dawn has over 15 years of experience in sales and marketing for pharmaceutical products and medical devices. Prior to joining Oyster Point, she spent 12 years at Allergan where she served as Executive Director for consumer eye care, which included the TrueTear® device and REFRESH® brands. Before that, Dawn was Executive Director of Strategic Marketing, responsible for leading the commercial strategy for the eye care pipeline, and led consumer marketing for RESTASIS®, which earned her recognition as a Top 25 DTC marketer. She was also a member of the Global Eye Care R&D Governance Board and was the commercial lead for the integration of Oculeve and ForSight VISION5. Dawn holds a B.S. in physical therapy from California State University, Long Beach and an M.B.A. from the University of Notre Dame.
Versant, NEA back Oyster Point Pharma developing novel therapies to treat ocular surface diseases — Nov 7, 2017.
Oyster Point Pharmaceuticals Inc., which is developing novel therapies for dry eye and other diseases of the ocular surface, today announced the completion of a $22 million Series A financing led by New Enterprise Associates and Versant Ventures. The proceeds from the round will fund Oyster Point's differentiated products through Phase II clinical trials.
Ocular surface diseases are disorders of the surface of the cornea. These conditions affect a large number of patients and can severely diminish eyesight and quality of life. For example, more than 16 million adults have diagnosed dry eye disease in the United States, according to published studies. Oyster Point's lead compounds for the treatment of ocular surface disease stimulate natural tear production.
"Currently marketed products and epidemiological studies have demonstrated the very large market potential for therapies to treat ocular surface diseases, but available prescription and over-the-counter therapeutics leave significant unmet need. We are very pleased with Oyster Point's clinical trial data to date, and there has been major interest from both doctors and patients to have our first-in-class products available," said Oyster Point President and CEO Jeffrey Nau, Ph.D., MMS.
Dr. Nau and other members of Oyster Point's leadership team have significant experience in the ophthalmology space, including a track record of successful product development. Dr. Nau was most recently with Ophthotech and previously with Genentech. Chairman Michael Ackermann, Ph.D., is former president and CEO of Oculeve, and CFO Mark Murray previously was CFO at innovative ophthalmic companies Oculeve, OptiMedica Corp. and Clarvista Medical.
"We believe Oyster Point's products have the potential to substantially improve on existing therapies and provide significant benefit to patients," said Clare Ozawa, Ph.D., a managing director at Versant. "We're pleased to join with NEA to bring this company to a significant value inflection point." "We are excited to team up with proven entrepreneurs in the space. We view this as a very compelling opportunity for dry eye and other ocular surface diseases," said Ali Behbahani, M.D., partner at NEA.
About Oyster Point
Oyster Point Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat ocular surface disease.
About Versant Ventures
Versant Ventures is a leading global healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great healthcare companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $2.3 billion under management and offices in North America and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm's founding in 1999, more than 65 Versant companies have achieved successful acquisitions or IPOs. For more information, please visit www.versantventures.com.
About New Enterprise Associates
New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With over $19 billion in cumulative committed capital since the firm's founding in 1977, NEA invests in technology and healthcare companies at all stages in a company's lifecycle, from seed stage through IPO. The firm's long track record of successful investing includes more than 210 portfolio company IPOs and more than 360 acquisitions. For additional information, visit www.nea.com.
Source: Versant Ventures